[The dose-response relationship in the use of hexabrix in angiography].
The authors present the results of a clinical trial of Hexabrix, a new radiopaque low osmolar agent, to be used in visceral catheterization translumbar angiography. Hexabrix was shown to reduce the frequency of side-effects by 40% as compared to triiodinated agents. The new agent causes no marked reactions in intraarterial administration even at a dose over 2 ml/kg. Hexabrix is an agent of choice to be used for patients at risk of angiographic investigation (allergy, advanced age, a severe general condition).
Tatochenko
K V
KV
Kondrashin
S A
SA
D000328:Adult; D000368:Aged; D000792:Angiography; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007485:Ioxaglic Acid / Q000009:adverse effects; D008297:Male; D008875:Middle Aged
D003974:Diatrizoate Meglumine; D007485:Ioxaglic Acid
Vzaimootnoshenie "doza-otvet" pri ispol'zovanii geksabriksa v angiografii.